Daily Oral Tenofovir and Emtricitabine-Tenofovir Preexposure Prophylaxis Reduces Herpes Simplex Virus Type 2 Acquisition Among Heterosexual HIV-1-Uninfected Men and Women: A Subgroup Analysis of a Randomized Trial.

Publication Type:

Journal Article


Annals of internal medicine, Volume 161, Issue 1, p.11-9 (2014)


2014, July 2014, Vaccine and Infectious Disease Division


Daily oral preexposure prophylaxis (PrEP) using the antiretroviral tenofovir disoproxil fumarate (TDF) alone or in combination with emtricitabine (FTC-TDF) reduces the risk for HIV-1 acquisition. Tenofovir has in vitro activity against herpes simplex virus type 2 (HSV-2).